By Barbara Obstoj-Cardwell. Editor
Last week’s important regulatory news included the US Food and Drug Administration (FDA) approving Travere Therapeutics’ Filspari for the reduction of proteinuria in adults with primary IgAN. Among research news, Actinium Pharmaceuticals released positive Phase III data on its myeloid leukemia candidate Iomab-12. On the M&A front, troubled US drug developer Jounce Therapeutics found a ‘white knight’, entering a reverse merger with the UK’s Redx Pharma. Deal-making saw AstraZeneca sign a licensing agreement with China-based KYM Biosciences for CMG901, a potential gastric cancer treatment to expand its own portfolio. Also, having already forked out around $1 billion in upfront and milestone payments, Swiss pharma giant Roche terminated its agreement with US biotech Blueprint Medicines on the cancer drug Gavreto.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze